Canntab Therapeutics Limited (CSE:PILL) (OTCQB:CTABF) (FRA:TBF1.F), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, has completed its first delivery of SKU's ordered by MediPharm Labs Corp (TSE:LABS) (OTCMKTS:MEDIF).
In a statement Tuesday, Canntab said the total purchase order is about $1.3 million and it intends to deliver the entire order by the end of 2020. So far, two of the five SKUs (stock-keeping unit) have been delivered.
READ: Canntab to launch in Australia and take part in the nation’s largest cannabis research study
"Our first commercial production and delivery of this initial portion of our order from MediPharm Labs Corp is a major milestone event for our company for three important reasons,” said Canntab CEO Larry Latowsky.
“First, this is evidence our science, quality assurance programs and production can be executed with the required standards to reflect our unique patented product of pressed tablets and caplets. Second, Canntab's wide range of products will finally be available to all Canadians through a variety of retail and wholesale channels.”
He added: “Finally, Canntab will be able to recognize revenue from its core product that will have a strong distribution base which will result in continuous sales through further expansion. Canntab will continue to enhance shareholder value by growing revenue through its domestic channels and expanding sales to international customers."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
